tiprankstipranks
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
US Market

Ultragenyx Pharmaceutical (RARE) Income Statement

Compare
798 Followers

Ultragenyx Pharmaceutical Income Statement

Last quarter (Q3 2024), Ultragenyx Pharmaceutical's total revenue was $139.49M, an increase of 42.27% from the same quarter last year. In Q3, Ultragenyx Pharmaceutical's net income was $-133.52M. See Ultragenyx Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 434.25M$ 363.33M$ 351.41M$ 271.03M$ 103.71M
Gross Profit
$ 389.04M$ 335.01M$ 335.40M$ 264.90M$ 94.71M
Operating Expenses
$ 958.25M$ 983.93M$ 717.13M$ 595.02M$ 518.88M
Depreciation and Amortization
$ 26.01M$ 18.20M$ 13.24M$ 12.26M$ 8.54M
EBITDA
$ -516.45M$ -640.51M$ -410.32M$ -139.81M$ -389.77M
Operating Income
$ -569.21M$ -648.92M$ -381.74M$ -330.12M$ -424.17M
Other Income/Expenses
$ -39.26M$ -52.81M$ -71.24M$ 144.76M$ 24.73M
Pretax Income
$ -608.46M$ -701.73M$ -452.98M$ -185.36M$ -399.44M
Net Income
$ -606.64M$ -707.42M$ -454.02M$ -186.57M$ -402.73M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -8.25$ -10.12$ -6.70$ -3.07$ -7.12
Diluted EPS
$ -8.25$ -10.12$ -6.70$ -3.07$ -7.12
Weighted Average Shares Outstanding
73.54M 69.91M 67.80M 60.85M 56.58M
Weighted Average Shares Outstanding (Diluted)
73.54M 69.91M 67.80M 60.85M 56.58M
Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis